Cadonilimab: all 158 studies that test it

Page 2 of 2. Open to participants first (105), then studies with results posted, then the rest; newest registration first within each.

• A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative ResectionRecruitingNCT05489289Phase 3
• AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian CancerRecruitingNCT05430906Phase 2
• AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung CancerRecruitingNCT05377658Phase 2
• A Study of AK109 Combined With AK104 in Patients With Advanced Solid TumorsRecruitingNCT05142423Phase 1/2
• A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaRecruitingNCT04982276Phase 1/2
• Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract CancerActive, not recruitingNCT07635290Phase 2
• SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal MetastasesActive, not recruitingNCT06940921Phase 1/2
• A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of RecurrenceTerminatedNCT06851104Phase 2
• AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic CancerActive, not recruitingNCT06646055Phase 1/2
• Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical CancerActive, not recruitingNCT06511726Phase 2
• Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLCActive, not recruitingNCT06477523Phase 1/2
• Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLCActive, not recruitingNCT06448910Phase 2
• Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct AdenocarcinomaStatus unknownNCT06383533Phase 2
• Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCCWithdrawnNCT06361758Phase 2
• Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)Active, not recruitingNCT06143748Phase 2
• Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell CarcinomaStatus unknownNCT06023875Phase 2
• Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) NegativeActive, not recruitingNCT06001151Phase 2
• AK104 for Recurrent or Metastatic Vulvar CancerTerminatedNCT05932212Phase 2
• AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung CancerActive, not recruitingNCT05904379Phase 1/2
• Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+TWithdrawnNCT05886257Phase 2
• Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal CancerStatus unknownNCT05839470Phase 2
• Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial CancerActive, not recruitingNCT05824481Phase 2
• Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05816499Phase 1/2
• A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell CarcinomaActive, not recruitingNCT05808608Phase 1/2
• Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal CancerCompletedNCT05792735Phase 2
• A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCCCompletedNCT05773105Phase 1/2
• Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+TStatus unknownNCT05760599Phase 2
• Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With CadonilimabStatus unknownNCT05737368Phase 1
• A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular CarcinomaActive, not recruitingNCT05644379Phase 1
• Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Active, not recruitingNCT05587374Phase 3
• AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)Status unknownNCT05578430Phase 2
• A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male SubjectsCompletedNCT05559554Phase 1
• Study of AK119 Combined With AK104 in Patients With Advanced Solid TumorsTerminatedNCT05559541Phase 1/2
• A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung CancerCompletedNCT05505825Phase 1/2
• Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal CancerActive, not recruitingNCT05426005Phase 1/2
• A Phase II Study of AK104 Plus Lenvatinib and TACE in HCCActive, not recruitingNCT05319431Phase 2
• A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant TumorsCompletedNCT05235542Phase 1/2
• A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical CancerActive, not recruitingNCT05235516Phase 3
• AK104 in Neoadjuvant Treatment of Cervical CancerCompletedNCT05227651Phase 2
• A Phase II Trial of AK104 in Advanced Non-Small Cell Lung CancerCompletedNCT05215067Phase 2
• Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the CervixActive, not recruitingNCT05063916Phase 2
• A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid TumoursCompletedNCT05021120Early Phase 1
• A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ AdenocarcinomaCompletedNCT05008783Phase 3
• A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical CancerActive, not recruitingNCT04982237Phase 3
• A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04728321Phase 2
• A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT04647344Phase 1/2
• A Trial of AK104 Plus Anlotinib in NSCLCCompletedNCT04646330Phase 1/2
• A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid TumorsCompletedNCT04572152Phase 1
• AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal CancerActive, not recruitingNCT04556253Phase 2
• A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid TumorsTerminatedNCT04547101Phase 2
• A Study of Combination Therapy in NSCLCStatus unknownNCT04544644Phase 2
• A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular CarcinomaCompletedNCT04444167Phase 1/2
• A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT04444141Phase 1/2
• A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical CancerCompletedNCT04380805Phase 2
• A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104CompletedNCT04349969Phase 1
• A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal CarcinomaCompletedNCT04220307Phase 2
• Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid TumorsCompletedNCT04172454Phase 1/2
• Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid TumorsCompletedNCT03261011Phase 1

← Cadonilimab overview